Application of TCF1-IRF4 in preparation of kit for predicting CLL disease prognosis

Abstract

The invention discloses application of TCF1-IRF4 in preparation of a kit for predicting CLL prognosis, (1) when the expression level of TCF1 is less than 0.67 and the expression level of IRF4 is greater than or equal to 1.99, the disease progression of a CLL patient is fast, and the possibility of poor clinical prognosis is large; (2) when the expression level of the TCF1 is less than 0.67 or the expression level of the IRF4 is greater than or equal to 1.99, the CLL patient is rapid in disease progress, and the possibility of poor clinical prognosis is relatively large; and (3) when the expression level of the TCF1 is greater than or equal to 0.67 and the expression level of the IRF4 is less than 1.99, the CLL patient has high possibility of disease stability and good clinical prognosis. The invention provides more clinical research data for deeply knowing the effect of the immune function state of the organism in the progress of CLL, and has wide application prospects in the aspects of predicting the disease progress speed and prognosis of CLL patients and evaluating the curative effects of small molecular targeted drugs, immune regulation treatment strategies and the like.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of TCF1-IRF4 in the preparation of a kit for predicting the prognosis of CLL disease. Background technique [0002] Chronic lymphocytic leukemia (CLL) is a malignant clonal proliferative tumor of mature B cells, with high clinical heterogeneity, most of them progress slowly, and the median survival time is 5-10 years. Biological characteristics such as TP53 abnormality, 11q-, and IGHV non-mutation are commonly used indicators for predicting disease stability and prognosis, but detection costs are high and time-consuming. The immune microenvironment disorder and T cell immune incompetence in CLL patients are gradually aggravated as the disease progresses. As an important pillar cell that constitutes its complex tumor microenvironment, T cells promote the survival and proliferation of CLL cells through the stimulation and activation of cytokine network or the direct action ...

AI Technical Summary

Problems solved by technology

We previously analyzed the TCGA database and found that CLL patients with high expression of IRF4 had rapid disease progression and short survival time. On the contrary, patients with low expression of IRF4 had stable disease and significantly prolonged survival time

Images